Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03109379 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder
A Phase 1 study, sponsored by Taris Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03109379: Completed Phase 1 study, sponsored by Taris Biomedical.
NCT03109379 is a Phase 1 study that has completed, run by Taris Biomedical. The registered enrollment target is 43 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03109379, a Phase 1 study, has completed, sponsored by Taris Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.
Primary Outcome
Safety will be assessed throughout the study based on reported AEs, investigational product events (IPEs), physical examinations (PEs), vital signs, clinical laboratory tests, scheduled cystoscopic examinations, bladder ultrasounds, bladder post-void residual volume (PVR), and the use of concomitant medications.
Interventions
- DRUG Trospium-Releasing Intravesical System (TAR-302-5018)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2017-04-04 |
| Est. Completion | 2019-09-27 |
| Phase | Phase 1 |
What the finished NCT03109379 record still lists
NCT03109379 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which Trospium-Releasing Intravesical System (TAR-302-5018) is the first listed.
NCT03109379 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03109379 about?
NCT03109379 is a clinical study titled "Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder". The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with idiopathic overactive bladder and urinary incontinence.
What is the current status of trial NCT03109379?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2017-04-04. Estimated completion is 2019-09-27.
What interventions are being tested in trial NCT03109379?
The interventions under investigation include: Trospium-Releasing Intravesical System (TAR-302-5018) (DRUG).
Who is sponsoring clinical trial NCT03109379?
This trial is sponsored by Taris Biomedical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03109379's enrollment target sits among peer trials
43 1100th of 2000 higher than 896 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI